Scott-Manno C

Language: Spanish
References: 6
Page: 10-11
PDF size: 22.35 Kb.

Text Extraction

Children with sickle cell disease are at risk for several unpredictable complications. In the past few years, several developments have brightened the outlook for patients with sickle cell disease. These include:
1. The therapeutic benefit of hydroxyurea in reducing the frequency of painful episodes and acute chest syndrome
2. The use of transcranial Doppler ultrasound to identify children at risk for CVA prior to the event
3. The introduction of a conjugate pneumococcal vaccine that will theoretically reduce the risk of pneumoccocal infection and sepsis in these susceptible children

REFERENCES

1. Adams RJ, McVie VC, Hsu L et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Dopple r ultrasonography. New Engl J Med 1998;339:5.

2. Adams RJ, McVie VC, Carl EM et al. Long-term risk in children with sickle cell disease screened with transcranial Doppler. Ann Neurol 1997;42:699.

3. Charache S et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 1995,332:1317.

4. Kinney T et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Blood 1999;94:1550.

5. Maier-Redelsperger M et al. Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients. Blood 1998;91:4472.

6. O’Brien KL, Swift AJ, Winkelstein JA et al. Safety and immunogenicity of heptavalent pneumoccal vaccine conjugated to CRM197 among infants with sickle cell disease. Pediatrics 2000;106,965.